# Pannex Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pannex-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.pannextherapeutics.com
- Latest round: Seed (Oct 12, 2021)
- Investors on record: 1

## About

Based in New York, US, and founded in 2020, Pannex Therapeutics Inc., is a pre-clinical stage biotech company that focuses on the development of novel drugs, intended for the treatment of various therapeutic areas and conditions. The company was founded by David Bravo (CEO), Thomas Gerlach, Gerhard Gross, and Jordan Marrocco, and in October 2021, Pannex Therapeutics Inc raised seed funding from SOSV.

The firm is primarily focused on developing a therapeutic platform that blocks Pannexin 1 (Panx 1) channels, a pharmacological target linked to chronic pain. Pannexin 1 blockers developed by the company are designed to target a variety of therapeutic regions, including cardiovascular, inflammatory, pulmonary, and CNS, allowing for the treatment of disorders such as autism, pain, cancer, epilepsy, migraine, and inflammation.

## Funding rounds

- Seed, Oct 12, 2021 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed